Email
Print
Large Molecule Injectable Drugs Market - By Drug Type (Monoclonal Antibodies, Vaccines, Insulin, Growth Factors, Other Large Molecules), By Therapeutic Area (Oncology, Autoimmune Disorders, Infectious Diseases, Cardiovascular Disorders Other Therapeutic Areas), By Route of Administration (intravenous, subcutaneous, intramuscular), By End users(Hospitals, specialty clinics, research institutions, homecare ) By Distribution Channel (Hospitals, pharmacies, retail pharmacies, specialty clinics, Online Pharmacies, etc.), By Geography - Global Opportunity Analysis & Industry Forecast, 2022-2030
Large Molecule Injectable Drugs Market Overview:
The global large molecule injectable drugs market size is expected to reach USD 168.3 billion by 2030, according to a report by Grand View Research. The market is projected to grow at a CAGR of 10.25% from 2022 to 2030. Large molecule injectable drugs are a type of drug that is administered by injection. They are typically large proteins or peptides that are produced using living organisms. Large molecule injectable drugs are often used to treat chronic diseases, such as cancer, rheumatoid arthritis, and multiple sclerosis.
The growth of the large molecule injectable drugs market is being driven by the increasing prevalence of chronic diseases, rising demand for self-administered injectable formulations, technological advancements in drug development, and growing approvals of new injectable drugs such as COVID-19 vaccines. The chronic diseases segment is the largest driver of the large molecule injectable drugs market. The increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and blood disorders is driving the demand for large molecule injectable drugs. These drugs are used to treat a variety of chronic diseases, and they are often the only effective treatment option available.
The self-administered injectable formulations segment is another major driver of the large molecule injectable drugs market. The increasing demand for self-administered injectable formulations is being driven by the growing number of people with chronic diseases who are able to self-administer their medications. Self-administered injectable formulations offer a number of advantages over traditional injectable formulations, such as convenience and flexibility. Technological advancements in drug development are also driving the growth of the large molecule injectable drugs market. Technological advancements such as gene therapy and cell therapy are leading to the development of new large molecule injectable drugs that are more effective and have fewer side effects than traditional drugs.
Market Snapshot:
-
Large Molecule Injectable Drugs Market - Report Coverage:
The “Large Molecule Injectable Drugs Market Report - Forecast (2022-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Biochar Market.
| Attribute | Segment |
|---|---|
By Drug Type |
|
By Therapeutic Area |
|
By end users |
|
By Route of Administration |
|
By Distribution Channel |
|
By Geography |
|
Large Molecule Injectable Drugs Market - Top Trends
Increasing prevalence of chronic diseases: The increasing prevalence of chronic diseases, such as cancer, autoimmune disorders, and blood disorders, is driving the demand for large molecule injectable drugs. These drugs are used to treat a variety of chronic diseases, and they are often the only effective treatment option available.
Rising demand for self-administered injectable formulations: The increasing demand for self-administered injectable formulations is being driven by the growing number of people with chronic diseases who are able to self-administer their medications. Self-administered injectable formulations offer a number of advantages over traditional injectable formulations, such as convenience and flexibility.
Technological advancements in drug development: Technological advancements in drug development, such as gene therapy and cell therapy, are leading to the development of new large molecule injectable drugs that are more effective and have fewer side effects than traditional drugs.
Growing approvals of new injectable drugs: In recent years, there have been a number of new injectable drugs approved by the FDA, such as the COVID-19 vaccines. These new drugs are driving the growth of the market, and they are expected to continue to do so in the coming years.
Focus on personalized medicine: There is a growing focus on personalized medicine in the large molecule injectable drugs market. This means that drugs are being developed that are tailored to the specific needs of individual patients. This is leading to the development of more effective and safer drugs.
Emerging markets: Emerging markets are also playing an increasingly important role in the large molecule injectable drugs market. This is due to the increasing prevalence of chronic diseases in these markets and the growing demand for effective treatment options.
The Large Molecule Injectable Drugs Market - Company Analysis
The large molecule injectable drugs market is a rapidly growing segment in the pharmaceutical industry. Large molecules, also known as biologics, are complex therapeutic substances that are produced through biotechnology processes. They include monoclonal antibodies, therapeutic proteins, peptides, and nucleic acid-based drugs. In this company analysis, I will provide information about some of the key players in the large molecule injectable drugs market as of my knowledge cutoff in September 2021. Please note that the market is dynamic, and there may have been changes since then. Here are a few prominent companies in this space:
Roche Holding AG: Roche is a leading global pharmaceutical company with a strong presence in the large molecule injectable drugs market. They have a diverse portfolio of biologic drugs, including monoclonal antibodies such as Herceptin, Avastin, and Rituxan. Roche has made significant advancements in the field of oncology and is involved in the development and commercialization of various targeted therapies.
Amgen Inc: Amgen is a biotechnology company known for its expertise in large molecule drugs. They have several successful biologic products in their portfolio, including Enbrel (etanercept) for autoimmune diseases and Neulasta (pegfilgrastim) for managing chemotherapy-induced neutropenia. Amgen invests heavily in research and development to discover and develop novel biologic therapies.
Johnson & Johnson: Johnson & Johnson is a multinational pharmaceutical and medical device company that has a strong presence in the large molecule injectable drugs market. They have a subsidiary called Janssen Pharmaceuticals, which focuses on developing biologic drugs. Janssen's portfolio includes biologic products such as Remicade (infliximab) for autoimmune disorders and Stelara (ustekinumab) for psoriasis and psoriatic arthritis.
AbbVie Inc.: AbbVie is a global biopharmaceutical company known for its expertise in immunology and oncology. They have a strong presence in the large molecule injectable drugs market with products like Humira (adalimumab), which is one of the top-selling biologic drugs worldwide. AbbVie also has a robust pipeline of biologic therapies in various stages of development.
Novartis International AG: Novartis is a multinational pharmaceutical company involved in the research, development, and manufacturing of innovative healthcare products. They have a portfolio of biologic drugs, including drugs like Lucentis (ranibizumab) for eye disorders and Entresto (sacubitril/valsartan) for heart failure. Novartis invests significantly in biologic research and development, aiming to address unmet medical needs.
Pfizer Inc: Pfizer is a global pharmaceutical company that has expanded its presence in the large molecule injectable drugs market through acquisitions and collaborations. They have a diverse portfolio of biologic drugs, including drugs like Xeljanz (tofacitinib) for rheumatoid arthritis and Ibrance (palbociclib) for certain types of breast cancer. Pfizer continues to invest in biotechnology to develop novel biologic therapies.
Key Market Players:
Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies players in the Large Molecule Injectable Drugs Market adopt. The top 10 companies in Large Molecule Injectable Drugs Market are listed below:
1. Roche Holding AG.
2. Amgen Inc.
3. Johnson & Johnson.
4. AbbVie Inc.
5. Novartis International AG.
6. Pfizer Inc.
7. Bristol Myers Squibb.
8. Merck & Co., Inc.
9. Eli Lilly and Company.
10. Sanofi.
Scope of the Report:
| Report Metric | Details |
|---|---|
Base Year Considered | 2021 |
Forecast Period | 2022–2030 |
CAGR | 10.25% |
Market Size in 2030 | USD 168.3 billion |
Segments Covered | Drug Type, Therapeutic Area, end users, Route of Administration, Distribution Channel. |
Geographies Covered | North America (U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), Rest of the World (Middle East and Africa). |
Key Market Players |
|
For more Lifesciences and Healthcare Market reports, please click here
1. Large Molecule Injectable Drugs Market Overview
1.1 Definitions and Scope
2. Large Molecule Injectable Drugs Market – Executive Summary
3. Large Molecule Injectable Drugs Market – Market Landscape
3.1 Company Benchmarking – Key Companies
3.2 Key Company Financial Analysis
3.3 Market Share Analysis – Key Companies
3.4 Patent Analysis
3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Large Molecule Injectable Drugs Market – Startup Company Scenario (Premium)
4.1 Investment
4.2 Revenue
4.3 Venture Capital and Funding Scenario
5. Large Molecule Injectable Drugs Market – Market Entry Scenario Premium (Premium)
5.1 Regulatory Scenario
5.2 New Business and Ease of Doing business index
5.3 Case Studies of Successful Ventures
6. Large Molecule Injectable Drugs Market – Market Forces
6.1 Market Drivers
6.2 Market Constraints
6.3 Porter’s Five Force Model
6.3.1 Bargaining Power of Suppliers
6.3.2 Bargaining Powers of Customers
6.3.3 Threat of New Entrants
6.3.4 Rivalry Among Existing Players
6.3.5 Threat of Substitutes
7. Large Molecule Injectable Drugs Market – Strategic Analysis
7.1 Value Chain Analysis
7.2 Opportunities Analysis
7.3 Market Life Cycle Analysis
8. Large Molecule Injectable Drugs Market – By Drug Type (Market Size - $Million/$Billion)
8.1 Monoclonal antibodies
8.1.1 Market Trends by Region
8.1.2. Market Share & Forecast by Region
8.2 Insulin
8.2.1 Market Trends by Region
8.2.2 Market Share & Forecast by Region
8.3 vaccines
8.3.1 Market Trends by Region
8.3.2 Market Share & Forecast by Region
8.4 Growth Factors
8.4.1 Market Trends by Region
8.4.2 Market Share & Forecast by Region
8.5 Others
9 Large Molecule Injectable Drugs Market –by Therapeutic Area (Market Size - $Million/$Billion)
9.1 Oncology
9.1.1 Market Share & Forecast by Region
9.1.2 Market Share & Forecast by Region
9.2 Autoimmune Disorders
9.2.1 Market Trends by Region
9.2.2 Market Share & Forecast by Region
9.3 Infectious Diseases
9.3.1 Market Trends by Region
9.3.2 Market Share & Forecast by Region
9.4 Cardiovascular Disorders
9.4.1 Market Trends by Region
9.4.2 Market Share & Forecast by Region
9.5 Other Therapeutic Areas
10 Large Molecule Injectable Drugs Market – by end users (Market Size - $Million/$Billion)
10.1 Hospitals
10.1.1 Market Trends by Region
10.1.2 Market Share & Forecast by Region
10.2 Specialty Clinics
10.2.1 Market Trends by Region
10.2.2 Market Share & Forecast by Region
10.3 research institutions
10.3.1 Market Trends by Region
10.3.2 Market Share & Forecast by Region
10.4 homecare settings
10.4.1 Market Trends by Region
10.4.2 Market Share & Forecast by Region
11 Large Molecule Injectable Drugs Market – by Route of Administration (Market Size - $Million/$Billion)
11.1 intravenous
11.1.1 Market Trends by Region
11.1.2 Market Share & Forecast by Region
11.2 subcutaneous
11.2.1 Market Trends by Region
11.2.2 Market Share & Forecast by Region
11.3 intramuscular
11.3.1 Market Trends by Region
11.3.2 Market Share & Forecast by Region
12 Large Molecule Injectable Drugs Market – by Distribution Channel (Market Size - $Million/$Billion)
12.1 Hospitals
12.1.1 Market Trends by Region
12.1.2 Market Share & Forecast by Region
12.2 Pharmacies
12.2.1 Market Trends by Region
12.2.2 Market Share & Forecast by Region
12.3 Retail Pharmacies
12.3.1 Market Trends by Region
12.3.2 Market Share & Forecast by Region
12.4 specialty clinics
12.5 Online Pharmacies
12.5.1 Market Trends by Region
12.5.2 Market Share & Forecast by Region
13 Large Molecule Injectable Drugs Market – by Geography (Market Size - $Million/$Billion)
13.1 North America
13.1.1 U.S.
13.1.2 Canada
13.1.3 Mexico
13.2 Europe
13.2.1 Germany
13.2.2 France
13.2.3 U.K.
13.2.4 Italy
13.2.5 Spain
13.2.6 Russia
13.2.7 Rest of Europe
13.3 Asia-Pacific
13.3.1 China
13.3.2 Japan
13.3.3 South Korea
13.3.4 India
13.3.5 Australia & New Zealand
13.3.6 Rest of Asia-Pacific
13.4 South America
13.4.1 Brazil
13.4.2 Argentina
13.4.3 Chile
13.4.4 Colombia
13.4.5 Rest of South America
13.5 Rest of the World
13.5.1 Middle East
13.5.2 Africa
14 Large Molecule Injectable Drugs Market – Market Entropy
14.1 New product launches
14.2 M&A’s, collaborations, JVs and partnerships
15 Large Molecule Injectable Drugs Market – Industry Competition Landscape (Premium)
15.1 Market Share Analysis
15.1.1 Market Share by Technology – Key Companies
15.1.2 Market Share by Country – Key Companies
15.1.3 Market Share by Region – Key Companies
15.2 Competition Matrix
15.3 Best Practices for Companies
16 Large Molecule Injectable Drugs Market – Key Company List by Country Premium (Premium)
17 Large Molecule Injectable Drugs Market – Company Analysis
17.1 Nature's Way.
17.2 Amgen Inc.
17.3 AbbVie Inc.
17.4 Johnson & Johnson.
17.5 Pfizer Inc.
17.6 Bristol Myers Squibb.
17.7 Merck & Co., Inc.
17.8 Eli Lilly and Company.
17.9 Sanofi.
17.10 Novartis International AG.
17.11 Company 11
17.12 Company 12
17.13 Company 13
17.14 Company 14
17.15 Company 15
17.16 Company 16
17.17 Company 17
17.18 Company 18
17.19 Company 19
17.20 Company 20
* "Financials would be provided to private companies on best-efforts basis."
Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.
The Large Molecule Injectable Drugs Market is forecast to grow at 10.25% during the forecast period 2022-2030.
The Global Large Molecule Injectable Drugs Market size is estimated to be USD 129.1 billion in 2022 and is projected to reach USD 168.3 billion by 2030.
The leading players in the Large Molecule Injectable Drugs Market are Roche Holding AG, Amgen Inc, Johnson & Johnson, AbbVie Inc., Novartis International AG, Pfizer Inc, Bristol Myers Squibb, Merck & Co., Inc, Eli Lilly and Company, Sanofi and others.